시장보고서

상품코드

1574948

CRBSI(카테터 관련 혈류 감염) 치료 시장 : 약제 클래스별, 투여 경로별, 적응증별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율 예측(2024-2032년)

CRBSI Treatment Market, By Drug Class, By Route of Administration, By Indication, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

발행일: 2024년 10월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 303 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

CRBSI(카테터 관련 혈류 감염) 치료 시장 규모는 2023년 15억 3,032만 달러로 2024년부터 2032년까지 연평균 복합 성장률(CAGR) 5.20%로 확대

CRBSI(카테터 관련 혈류 감염) 치료 시장 - 시장 역학

카테터 관련 혈류 감염의 만연이 효과적인 치료에 대한 수요를 끌어 올립니다.

CRBSI(카테터 관련 혈류 감염) 치료의 유행 증가는 CRBSI 치료 시장의 중요한 촉진요인입니다. CRBSI와 관련된 위험에 대한 환자와 건강 관리 제공업체의 의식 증가는 예방 전략의 중요성으로 이어지고 있습니다. 헬스케어 부문이 환자의 안전을 우선하고, 원내 감염의 삭감에 노력하는 가운데, CRBSI 치료에 대한 수요는 계속 확대되고 있어 헬스 케어 시장에서의 연구개발의 중요한 분야가 되고 있습니다.

미국 질병 예방관리센터(CDC)에 따르면 미국에서는 매년 약 25만 건의 혈류 감염이 발생하고 있으며, 그 중 상당수가 중심 정맥 카테터와 관련되어 있습니다. 이것은 효과적인 치료와 예방 조치의 긴급한 필요성을 돋보이게합니다. 의료기관에서는 항균제 함침 카테터 등의 고급 감염 제어 프로토콜의 채용과 카테터 케어에 관한 의료 스태프에 대한 훈련 강화가 진행되고 있습니다.

CRBSI 치료 시장 - 주요 인사이트

우리의 리서치 애널리스트의 분석에 따르면 세계 시장은 예측 기간(2024-2032년)에 약 5.20%의 연평균 복합 성장률(CAGR)로 매년 성장할 것으로 예측됩니다.

약물 등급별로 반코마이신은 2023년에 가장 큰 시장 점유율을 보여줄 것으로 예상됐습니다.

적응증별로, 박테리아 감염은 2023년의 주요 유형이었습니다.

투여 경로별로는 2023년에는 주사제가 주요 유형이 되었습니다.

지역별로는 북미가 2023년 매출에서 최고

CRBSI 치료 시장 - 세분화 분석 :

세계의 CRBSI 치료 시장은 약물 클래스별, 투여 경로별, 적응증별, 지역별로 구분됩니다.

시장은 약물 등급별로 7가지로 분류됩니다다: 클로사실린, 세프타디뮴, 세파졸린, 답토마이신, 반코마이신, 테이코플라닌, 에키노칸딘 등. 반코마이신은 CRBSI 치료 시장에서 가장 지배적인 부문입니다. 이 항생제는 CRBSI를 유발하는 메티실린 내성 황색 포도상 구균(MRSA)에 잘 작용합니다. 신뢰성이 높고 많은 유형의 박테리아에 효과적이므로 건강 관리 제공업체에게 선호됩니다. 반코마이신은 오랫동안 사용되어 왔으며 안전성이 높기 때문에 더욱 신뢰할 수 있습니다. 항생제 내성이 증가하는 동안, 반코마이신과 같은 효과적인 치료의 필요성은 여전히 높습니다. 전반적으로, 그 효능과 의료 종사자의 신뢰는 CRBSI 치료의 최상위에 계속 군림합니다.

시장은 적응증별로 세 가지 범주로 나뉩니다: 세균 감염증, 진균 감염증, 바이러스 및 기생충 감염증 등. 박테리아 감염은 CRBSI(카테터 관련 혈류 감염) 치료 시장의 가장 큰 부분을 차지합니다. 박테리아는 이러한 감염의 가장 흔한 원인이며 심각한 건강 문제로 이어질 수 있습니다. 치료에는 대개 많은 유형의 박테리아에 효과적인 항생제가 사용됩니다. 카테터를 사용하는 환자에서 박테리아 감염이 많기 때문에 이러한 치료에 대한 수요가 증가하고 있습니다. 또한 건강 관리 제공업체는 박테리아 감염으로 인한 합병증을 줄이기 위해 신속한 해결책에 중점을두고 있으며,이 부분은 시장의 추가 성장을 뒷받침하고 있습니다.

CRBSI 치료 시장 - 지리적 통찰

북미 CRBSI(카테터 관련 혈류 감염) 치료 시장은 빠르게 성장하고 있습니다. 이 성장은 주로 더 많은 사람들이 병원에 입원하고 중심 정맥 카테터를 사용하기 때문입니다. 병원은 더 나은 감염 대책에 주력하고 있으며 효과적인 치료에 대한 수요가 높아지고 있습니다. 감염 통제 프로그램에 대한 정부의 지원도이 시장의 중요한 촉진요인입니다. 의료 규제의 강화로 병원은 개선된 기술과 제품을 채택하게 되었습니다. 그 결과 환자는 더 안전하고 효과적인 치료를 받을 수 있습니다.

CRBSI 치료 시장 - 경쟁 구도:

CRBSI(카테터 관련 혈류 감염) 치료 시장은 경쟁이 심하고, Bard Medical (BD), Medtronic, Teleflex 등 중요한 기업이 진입하고 있습니다. Bard Medical은 혁신적인 카테터 디자인으로 유명합니다. Medtronic은 세계 다양한 제품을 제공합니다. Teleflex는 감염 예방을 위한 고급 디자인으로 환자의 안전을 중시합니다.

Smith's Medical은 버스큘러 액세스를 전문으로 하며 품질과 안전성에 중점을 둡니다. Fresenius Kabi는 중환자 케어 제품으로 유명하며, AngioDynamics는 낮은 침습 처치에 중점을 둡니다. B. Braun Melsungen AG는 다양한 의료기기를 제공하고 지속가능성을 중시합니다. 이 회사들은 새로운 솔루션을 창출하고 감염 예방을 개선하기 위해 노력하고 있으며 시장을 활발하고 역동적으로 만듭니다.

소개
북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 이탈리아
- 영국
- 프랑스
- 러시아
- 네덜란드
- 스웨덴
- 폴란드
- 기타
아시아태평양
- 개요
- 아시아태평양의 주요 제조업체
- 인도
- 중국
- 일본
- 한국
- 호주
- 태국
- 인도네시아
- 필리핀
- 기타
라틴아메리카
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 터키
- 알제리
- 이집트
- 기타

제11장 주요 벤더 분석-CRBSI 치료 업계

경쟁 대시보드
기업 프로파일
- Bard Medical
- Medtronic
- Teleflex
- Smith's Medical
- Halyard Health
- Fresenius Kabi
- AngioDynamics
- Vygon
- B. Braun Melsungen AG
- Nipro Corporation
- Cook Medical
- Amsino International
- Merit Medical Systems
- Pall Corporation
- CR Bard
- Ruhof Healthcare
- Inspire Medical Systems
- Abbott Laboratories

제12장 애널리스트의 전방위 전망

JHS 24.11.06

REPORT HIGHLIGHT

CRBSI Treatment Market size was valued at USD 1,530.32 Million in 2023, expanding at a CAGR of 5.20% from 2024 to 2032.

CRBSI stands for Catheter-Related Bloodstream Infections. It happens when bacteria enter the bloodstream through a catheter, a tube used for medical treatments. The treatment market for CRBSI includes various products and therapies designed to prevent and manage these infections. This market offers antibiotics, antiseptics, and advanced catheter designs that reduce infection risk. Hospitals and healthcare providers invest in these solutions to improve patient safety and outcomes. The goal is to minimize infections, which can lead to serious health issues and longer hospital stays.

CRBSI Treatment Market- Market Dynamics

The prevalence of catheter-related infections boosts demand for effective treatments.

The rising prevalence of catheter-related bloodstream infections (CRBSI) is a significant driver for the CRBSI treatment market. Growing awareness among patients and healthcare providers about the risks associated with CRBSIs is leading to a greater emphasis on prevention strategies. As the healthcare sector prioritizes patient safety and strives to reduce hospital-acquired infections, the demand for CRBSI treatments continues to grow, making it a crucial area for research and development in the healthcare market.

According to the Centers for Disease Control and Prevention (CDC), about 250,000 cases of bloodstream infections occur in the U.S. each year, with many linked to central line catheters. This highlights the urgent need for effective treatments and preventive measures. Healthcare institutions are increasingly adopting advanced infection control protocols, such as antimicrobial-impregnated catheters, and enhanced training for healthcare staff on catheter care.

CRBSI Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.20% over the forecast period (2024-2032)

Based on Drug Class segmentation, Vancomycin was predicted to show maximum market share in the year 2023

Based on indication, Bacterial Infections was the leading type in 2023

Based on Route of Administration segmentation, Injectable was the leading type in 2023

based on Region, North America was the leading revenue generator in 2023

CRBSI Treatment Market- Segmentation Analysis:

The Global CRBSI Treatment Market is segmented based on Drug Class, Route of Administration, Indication, and Region.

The market is divided into Seven categories based on Drug Class: Cloxacillin, Ceftazidime, Cefazoline, Daptomycin, Vancomycin, Teicoplanin, Echinocandin, and Others. Vancomycin is the most dominant segment in the CRBSI treatment market. This antibiotic works well against methicillin-resistant Staphylococcus aureus (MRSA), which often causes these infections. Healthcare providers like it because it is reliable and effective against many types of bacteria. Vancomycin has been used for a long time and has a strong safety record, making it even more trusted. As antibiotic resistance increases, the need for effective treatments like Vancomycin is still high. Overall, its effectiveness and the trust of medical professionals keep it at the top of CRBSI treatment.

The market is divided into three categories based on the Indication: Bacterial Infections, Fungal Infections, Viral and Parasitic Infections, and Others. Bacterial infections are the biggest part of the CRBSI (Catheter-Related Bloodstream Infection) treatment market. bacteria are the most common cause of these infections and can lead to serious health problems. Treatments usually involve antibiotics, which are effective against many types of bacteria. The high number of bacterial infections in patients with catheters increases the demand for these treatments. Also, healthcare providers focus on quick solutions to reduce complications from bacterial infections, which helps this part of the market grow even more.

CRBSI Treatment Market- Geographical Insights

North America's catheter-related bloodstream infection (CRBSI) treatment market is growing quickly. This growth is mainly because more people are admitted to hospitals and using central venous catheters. Hospitals are focusing on better infection control, increasing the demand for effective treatments. Government support for infection control programs is also an important driver for this market. Stricter healthcare regulations encourage hospitals to adopt improved practices and products. As a result, patients are receiving safer and more effective care.

CRBSI Treatment Market- Competitive Landscape:

The catheter-related bloodstream infections (CRBSI) market is competitive and includes important companies like Bard Medical (BD), Medtronic, and Teleflex. Bard Medical is known for its innovative catheter designs. Medtronic offers a wide range of products around the world. Teleflex focuses on patient safety with advanced designs to prevent infections.

Smith's Medical specializes in vascular access and puts a strong emphasis on quality and safety. Fresenius Kabi is well-known for its critical care products, and AngioDynamics focuses on minimally invasive procedures. B. Braun Melsungen AG offers a variety of medical devices and values sustainability. These companies work hard to create new solutions and improve infection prevention, making the market active and dynamic.

Recent Developments:

In August 2023, Citius Pharmaceuticals, Inc. announced a significant milestone for the clinical trial of Mino-Lok, an antibiotic lock solution designed to preserve catheters in patients with catheter-related bloodstream infections. The company reported that all 92 required events to complete the trial have been achieved. Some patients are still undergoing treatment, which may result in additional events.

In July 2023, Teva Pharmaceuticals, Inc. and Alvotech revealed their intention to strengthen their existing strategic partnership aimed at developing and launching several biosimilar candidates. As part of this collaboration, Teva will invest an additional US$ 40 million by purchasing subordinated convertible bonds to be issued by Alvotech.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CRBSI TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Bard Medical
Medtronic
Teleflex
Smith's Medical
Halyard Health
Fresenius Kabi
AngioDynamics
Vygon
B. Braun Melsungen AG
Nipro Corporation
Cook Medical
Amsino International
Merit Medical Systems
Pall Corporation
C.R. Bard
Ruhof Healthcare
Inspire Medical Systems
Abbott Laboratories

GLOBAL CRBSI TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

Cloxacillin
Ceftazidime
Cefazoline
Daptomycin
Vancomycin
Teicoplanin
Echinocandin
Others

GLOBAL CRBSI TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

Oral
Injectable

GLOBAL CRBSI TREATMENT MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

Bacterial Infections
Fungal Infection
Viral and Parasitic Infections
Others

GLOBAL CRBSI TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. CRBSI Treatment Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. CRBSI Treatment Market Snippet by Drug Class
- 2.1.2. CRBSI Treatment Market Snippet by Route of Administration
- 2.1.3. CRBSI Treatment Market Snippet by Indication
- 2.1.4. CRBSI Treatment Market Snippet by Country
- 2.1.5. CRBSI Treatment Market Snippet by Region
2.2. Competitive Insights

3. CRBSI Key Market Trends

3.1. CRBSI Treatment Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. CRBSI Treatment Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. CRBSI Treatment Market Opportunities
3.4. CRBSI Treatment Market Future Trends

4. CRBSI Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. CRBSI Treatment Market: COVID-19 Impact Analysis

5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments

6. CRBSI Treatment Market Landscape

6.1. CRBSI Treatment Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. CRBSI Treatment Market - By Drug Class

7.1. Overview
- 7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
- 7.1.2. Cloxacillin
- 7.1.3. Ceftazidime
- 7.1.4. Cefazoline
- 7.1.5. Daptomycin
- 7.1.6. Vancomycin
- 7.1.7. Teicoplanin
- 7.1.8. Echinocandin
- 7.1.9. Others

8. CRBSI Treatment Market - By Route of Administration

8.1. Overview
- 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
- 8.1.2. Oral
- 8.1.3. Injectable

9. CRBSI Treatment Market - By Indication

9.1. Overview
- 9.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
- 9.1.2. Bacterial Infections
- 9.1.3. Fungal Infection
- 9.1.4. Viral and Parasitic Infections
- 9.1.5. Others

10. CRBSI Treatment Market- By Geography

10.1. Introduction
- 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
10.2. North America
- 10.2.1. Overview
- 10.2.2. CRBSI Key Manufacturers in North America
- 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 10.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.2.6. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.2.7. U.S.
  - 10.2.7.1. Overview
  - 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.7.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.2.7.5. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.2.8. Canada
  - 10.2.8.1. Overview
  - 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.8.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.2.8.5. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.3. Europe
- 10.3.1. Overview
- 10.3.2. CRBSI Key Manufacturers in Europe
- 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 10.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.3.6. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.3.7. Germany
  - 10.3.7.1. Overview
  - 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.7.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.3.7.5. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.3.8. Italy
  - 10.3.8.1. Overview
  - 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.8.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.3.8.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.3.8.5. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.3.9. United Kingdom
  - 10.3.9.1. Overview
  - 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.9.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.3.9.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.3.9.5. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.3.10. France
  - 10.3.10.1. Overview
  - 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.10.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.3.10.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.3.10.5. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.3.11. Russia
  - 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.11.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.3.11.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.3.11.4. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.3.12. Netherlands
  - 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.12.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.3.12.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.3.12.4. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.3.13. Sweden
  - 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.13.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.3.13.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.3.13.4. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.3.14. Poland
  - 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.14.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.3.14.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.3.14.4. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.3.15. Rest of Europe
  - 10.3.15.1. Overview
  - 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.3.15.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.3.15.5. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.4. Asia Pacific (APAC)
- 10.4.1. Overview
- 10.4.2. CRBSI Key Manufacturers in Asia Pacific
- 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 10.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.4.6. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.4.7. India
  - 10.4.7.1. Overview
  - 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.7.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.4.7.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.4.7.5. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.4.8. China
  - 10.4.8.1. Overview
  - 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.8.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.4.8.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.4.8.5. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.4.9. Japan
  - 10.4.9.1. Overview
  - 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.9.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.4.9.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.4.9.5. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.4.10. South Korea
  - 10.4.10.1. Overview
  - 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.10.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.4.10.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.4.10.5. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.4.11. Australia
  - 10.4.11.1. Overview
  - 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.11.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.4.11.5. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.4.12. Thailand
  - 10.4.12.1. Overview
  - 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.12.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.4.12.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.4.12.5. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.4.13. Indonesia
  - 10.4.13.1. Overview
  - 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.13.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.4.13.5. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.4.14. Philippines
  - 10.4.14.1. Overview
  - 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.14.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.4.14.5. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.4.15. Rest of APAC
  - 10.4.15.1. Overview
  - 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.4.15.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.4.15.5. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.5. Latin America
- 10.5.1. Overview
- 10.5.2. CRBSI Key Manufacturers in Latin America
- 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 10.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.5.6. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.5.7. Brazil
  - 10.5.7.1. Overview
  - 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.7.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.5.7.5. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.5.8. Mexico
  - 10.5.8.1. Overview
  - 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.8.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.5.8.5. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.5.9. Argentina
  - 10.5.9.1. Overview
  - 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.9.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.5.9.5. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.5.10. Colombia
  - 10.5.10.1. Overview
  - 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.10.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.5.10.5. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.5.11. Rest of LATAM
  - 10.5.11.1. Overview
  - 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.5.11.5. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10.6. Middle East and Africa
- 10.6.1. Overview
- 10.6.2. CRBSI Key Manufacturers in Middle East and Africa
- 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 10.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.6.6. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.6.7. Saudi Arabia
  - 10.6.7.1. Overview
  - 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.6.7.5. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.6.8. United Arab Emirates
  - 10.6.8.1. Overview
  - 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.6.8.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.6.8.5. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.6.9. Israel
  - 10.6.9.1. Overview
  - 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.9.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.6.9.5. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.6.10. Turkey
  - 10.6.10.1. Overview
  - 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.10.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.6.10.5. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.6.11. Algeria
  - 10.6.11.1. Overview
  - 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.11.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.6.11.5. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.6.12. Egypt
  - 10.6.12.1. Overview
  - 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.12.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.6.12.5. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.6.13. Rest of MEA
  - 10.6.13.1. Overview
  - 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.6.13.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.6.13.5. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- CRBSI Industry

11.1. Competitive Dashboard
11.2. Company Profiles
- 11.2.1. Bard Medical
- 11.2.2. Medtronic
- 11.2.3. Teleflex
- 11.2.4. Smith's Medical
- 11.2.5. Halyard Health
- 11.2.6. Fresenius Kabi
- 11.2.7. AngioDynamics
- 11.2.8. Vygon
- 11.2.9. B. Braun Melsungen AG
- 11.2.10. Nipro Corporation
- 11.2.11. Cook Medical
- 11.2.12. Amsino International
- 11.2.13. Merit Medical Systems
- 11.2.14. Pall Corporation
- 11.2.15. C.R. Bard
- 11.2.16. Ruhof Healthcare
- 11.2.17. Inspire Medical Systems
- 11.2.18. Abbott Laboratories

12. 360 Degree Analyst View

13. Appendix

13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us